Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Ann Clin Microbiol Antimicrob ; 10: 26, 2011 Jun 09.
Article in English | MEDLINE | ID: mdl-21658248

ABSTRACT

BACKGROUND: There is no clear relationship between in vitro bactericidal activity tests and clinical outcome. We studied bactericidal activity of oxacillin, vancomycin and teicoplanin against Staphylococcus aureus isolates in patients with endocarditis and then we sought to determine if there was a relationship between in vitro bactericidal activity and clinical outcome. METHODS: Minimal bacteriostatic and minimal bactericidal concentrations were determined for Staphylococcus aureus strains isolated from patients with endocarditis following standardized methods. Medical records were reviewed retrospectively to collect data on antimicrobial susceptibility at admission, antimicrobial therapy, need for surgery, embolic events and outcome. RESULTS AND DISCUSSION: Sixty-two Staphylococcus aureus strains were studied in 62 patients with endocarditis. Overall, 91.9% definite, 21% methicillin resistant and 72.6% cured. Surgery was performed in 32.3% and embolic events were documented in 64.5%. Tolerance to oxacillin and teicoplanin was more common than vancomycin tolerance among methicillin susceptible Staphylococcus aureus. Among methicillin resistant Staphylococcus aureus teicoplanin was shown to have a higher rate of tolerance than vancomycin. No statistically significant differences on clinical outcome between oxacillin tolerant and oxacillin non tolerant Staphylococcus aureus infections were observed. Tolerance to oxacillin did not adversely affect clinical outcomes of patients with methicillin susceptible Staphylococcus aureus endocarditis treated with a combination of antimicrobials including oxacillin. The cure rate was significantly lower among patients with methicillin resistant Staphylococcus aureus endocarditis. CONCLUSIONS: In vitro bactericidal test results were not valid predictors of clinical outcome. Physicians need to use additional parameters when treating patients with staphylococcal endocarditis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Glycopeptides/therapeutic use , Oxacillin/therapeutic use , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Adult , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Drug Therapy, Combination , Endocarditis, Bacterial/microbiology , Female , Glycopeptides/pharmacology , Humans , Male , Oxacillin/pharmacology , Retrospective Studies , Serum Bactericidal Test , Staphylococcal Infections/microbiology , Staphylococcus aureus/isolation & purification , Treatment Outcome
2.
Scand J Infect Dis ; 39(9): 805-12, 2007.
Article in English | MEDLINE | ID: mdl-17701720

ABSTRACT

Cardiovascular disease (CVD) is an increasing concern for human immunodeficiency virus (HIV)-infected patients, and risk assessment is recommended in routine HIV care. The absolute cardiovascular risk in an individual is determined by several factors, and various algorithms may be applied. To date, few comparisons of HIV patients with persons of the same age from the general population have been conducted. We hypothesized that the calculated risk of CVD may be increased in HIV patients. The probability for acute coronary events within 10 y (Framingham Risk Score) and the probability for fatal cardiovascular disease (SCORE algorithm) were assessed in 403 consecutive HIV-positive subjects free from overt cardiovascular disease, as well as in 96 age- and gender-matched control subjects drawn from the general population living in the same geographical area. The average 10-y risk for acute coronary events (Framingham Risk Score) was 7.0%+/-5% in HIV subjects and 6.3%+/-5% in the control group (p =0.32). The 10-y estimated risk for cardiovascular mortality (SCORE algorithm) was 1.23%+/-2.3% and 0.83%+/-0.9%, respectively (p =0.01). The main contributor to the increased CVD risk was the high proportion of smokers, but not an increase in cholesterol level. In conclusion, a limited increase in estimated risk of CVD was found in HIV-infected patients compared to the general population. In HIV-infected individuals other factors of less value in the general population and not included in any cardiovascular algorithm might be important. In our patients intervention to modify traditional risk factors should be addressed primarily towards modifying smoking habits.


Subject(s)
Acquired Immunodeficiency Syndrome/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/virology , Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/virology , Adult , Cross-Sectional Studies , Female , Humans , Italy/epidemiology , Male , Middle Aged , Outpatients , Risk Factors , Smoking/epidemiology
4.
Haematologica ; 91(7): 980-2, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16818288

ABSTRACT

The prevalence, incidence and clinical course of viral hepatitis were prospectively determined in consecutive recipients of T-cell depleted hematopoieic stem cell transplants (49 mismatched, 60 matched, mean age 38 years; range 11-65). The prevalence of hepatitis B virus (HBV) was 15.6% and that of hepatitis C virus was 3.7% (HCV). HBV reactivated in one patient. Another developed ex novo acute hepatitis B which progressed to chronic hepatitis. There were no new cases of hepatitis C or worsening of pre-transplant HCV infections. HBV and HBC did not affect the outcome of T-cell depleted hematopoieic stem cell transplantation. Surveillance is important given the risk of HCV and HBV infection and/or reactivation and the efficacy of the new anti-hepatitis drugs.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Hepatitis B/etiology , Hepatitis C/etiology , Adolescent , Adult , Aged , Child , Hematopoietic Stem Cell Transplantation/methods , Histocompatibility , Humans , Incidence , Lymphocyte Depletion , Middle Aged , Prevalence , Prospective Studies , Transplantation, Homologous , Treatment Outcome
5.
Scand J Infect Dis ; 38(1): 74-5, 2006.
Article in English | MEDLINE | ID: mdl-16338845

ABSTRACT

Psoriasis has been classified as a T-cell-mediated inflammatory disease. The paradoxical exacerbation of psoriasis in AIDS has not been fully explained. We describe a case of a 45-y-old male with AIDS whose coincidental psoriasis resolved following antiretroviral therapy. Dramatic improvement was seen 4 weeks after combination antiretroviral therapy including enfuvirtide was started. In advanced HIV disease psoriasis could represent a clinical index of progression of HIV disease. Several pathogenetic factors involved in the clinical manifestations of psoriasis in the HIV-infected population are discussed.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Acquired Immunodeficiency Syndrome/drug therapy , Anti-HIV Agents/therapeutic use , Psoriasis/complications , Psoriasis/drug therapy , Antiretroviral Therapy, Highly Active , Humans , Male , Middle Aged , Psoriasis/pathology
7.
Recenti Prog Med ; 96(6): 291-2, 2005 Jun.
Article in Italian | MEDLINE | ID: mdl-16078758

ABSTRACT

Among the post neurosurgery infections the meningitis due to Corynebacterium jeikeium are rare, particularly without central nervous system devices. We report a case of a 78 year-old patient with chronic myeloproliferative syndrome, who developed an acute meningeal syndrome by Corynebacterium jeikeium post hypophyseal macroadenoma resection.


Subject(s)
Corynebacterium Infections/microbiology , Corynebacterium/isolation & purification , Cross Infection/microbiology , Immunocompromised Host , Meningitis, Bacterial/microbiology , Neurosurgical Procedures/adverse effects , Aged , Anti-Bacterial Agents/therapeutic use , Corynebacterium Infections/diagnosis , Corynebacterium Infections/drug therapy , Cross Infection/diagnosis , Cross Infection/drug therapy , Humans , Male , Meningitis, Bacterial/diagnosis , Meningitis, Bacterial/drug therapy , Treatment Outcome
8.
Arterioscler Thromb Vasc Biol ; 25(11): 2381-5, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16123321

ABSTRACT

BACKGROUND: The role of antiretroviral therapy in acceleration of atherosclerosis in patients with human immunodeficiency virus (HIV) infection is controversial. We hypothesized that aortic stiffness, an early marker of arteriosclerosis, may be increased in HIV patients treated with protease inhibitors. METHODS AND RESULTS: In 32 HIV-infected patients treated with protease inhibitors and 32 age-, sex-, and blood pressure-matched HIV-uninfected control subjects, we obtained aortic pulse wave velocity and central aortic pressure waveform, from which aortic augmentation was calculated. HIV patients had a higher aortic pulse wave velocity (7.6+/-1.1 versus 6.8+/-1.2 m x s(-1), P=0.015) and aortic augmentation (6.8+/-5 versus 4.6+/-4 mm Hg, P=0.037) than control subjects. Age and HIV infection (both P<0.05) independently predicted aortic pulse wave velocity when a consistent number of cardiovascular risk factors was simultaneously controlled for. The cumulative duration of treatment was a predictor of aortic pulse wave velocity, each 5 years of treatment duration being independently related to a 1.35 m x s(-1) increase in pulse wave velocity. CONCLUSIONS: Aortic stiffness is increased in HIV-positive individuals receiving antiretroviral therapy including a protease inhibitor. Pulse wave velocity increases with longer exposure to protease inhibitors. We hypothesize that arteriosclerosis is a side effect of antiretroviral treatment including a protease inhibitor.


Subject(s)
Atherosclerosis/chemically induced , Atherosclerosis/epidemiology , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Adult , Aortic Diseases/chemically induced , Aortic Diseases/diagnosis , Aortic Diseases/epidemiology , Atherosclerosis/diagnosis , Blood Pressure , Female , HIV Infections/epidemiology , Humans , Linear Models , Male , Middle Aged , Pulsatile Flow , Risk Factors
9.
New Microbiol ; 28(2): 145-9, 2005 Apr.
Article in English | MEDLINE | ID: mdl-16035259

ABSTRACT

Over a period of 18 months 3 clusters of central venous catheter-related Ralstonia pickettii bacteremia occurred in 3 different units of the same hospital. In order to investigate the relatedness of the clinical isolates we studied 15 strains using pulsed-field gel electrophoresis (PFGE) and randomly amplified polymorphic DNA (RAPD) techniques. The combined analysis of the results obtained by these two methods led us to conclude that all the patients except one were infected by a single clone comprising two variants circulating in the units. Only one case was due to a different strain, probably originating outside the ward. PFGE and RAPD appear to be discriminatory techniques to study the clonal relationship among the isolates and can represent a good tool to perform the epidemiological investigation of an outbreak.


Subject(s)
Bacteremia/epidemiology , Catheterization, Central Venous/adverse effects , Cross Infection/epidemiology , Ralstonia/classification , Ralstonia/genetics , Random Amplified Polymorphic DNA Technique/methods , Bacteremia/microbiology , Bacterial Typing Techniques , Cross Infection/microbiology , Electrophoresis, Gel, Pulsed-Field , Gram-Negative Bacterial Infections/epidemiology , Gram-Negative Bacterial Infections/microbiology , Humans , Ralstonia/isolation & purification
10.
Infez Med ; 13(1): 45-7, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15888983

ABSTRACT

In the last few years, substantial evidence has been provided on peripheral nervous involvement in infection by hepatitis C virus (HCV), whilst central nervous involvement is rare. Here, we report a case of acute transverse myelitis in a woman developing 4 years after documented HCV seropositivity, associated with intrathecal anti-HCV protein IgG. Isoelectrofocusing of all CSF samples before and after immunoabsorption with recombinant structural HCV proteins revealed disappearance or marked decrease of some oligoclonal IgG bands suggesting binding to HCV proteins. To our knowledge, this is the first report of acute myelitis associated with intrathecal immune response against HCV proteins. This finding suggests that in acute myelitis of unknown aetiology, testing CSF for HCV RNA and related antibodies is warranted.


Subject(s)
Hepatitis C/complications , Myelitis, Transverse/etiology , Acute Disease , Autoimmunity , Female , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/immunology , Hepatitis C Antibodies/analysis , Humans , Immunoblotting , Immunoglobulin G/analysis , Isoelectric Focusing , Magnetic Resonance Imaging , Middle Aged , Myelitis, Transverse/cerebrospinal fluid , Myelitis, Transverse/diagnosis , Myelitis, Transverse/immunology , RNA, Viral/analysis , Time Factors , Viral Proteins/immunology
12.
Recenti Prog Med ; 95(11): 521-4, 2004 Nov.
Article in Italian | MEDLINE | ID: mdl-15598089

ABSTRACT

Because hepatitis C virus (HCV) and human immunodeficiency virus (HIV) share common transmission pathways, HIV-HCV co-infection is frequent, involving about 40% of seropositive subjects particularly injection drug users and patients with hemophilia. We performed a retrospective analysis on clinical, epidemiological and therapeutical aspects in a population of HIV-HCV coinfected patients, observed in our Department during the period 2001-2003. Forty per cent of 404 observed patients had a co-infection; 90% of those were drug addicts and most (90.2%) were on HAART treatment. Seventy-three per cent of co-infected patients showed transaminases alterations, and 85% had detectable viremia. Prevalent genotypes were 1 (44.6%) and 3 (36.4%). The association PEG-IFN and ribavirine obtained sustained responses in 55% of 9 treated patients.


Subject(s)
HIV Infections/complications , Hepatitis C/complications , Adult , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Biopsy , Data Interpretation, Statistical , Drug Therapy, Combination , Female , Genotype , HIV Infections/diagnosis , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/pathology , Hepacivirus/genetics , Hepatitis C/diagnosis , Hepatitis C/drug therapy , Hepatitis C/epidemiology , Hepatitis C/pathology , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Interferon-alpha/therapeutic use , Interferons/administration & dosage , Interferons/therapeutic use , Italy/epidemiology , Liver/pathology , Male , Patient Compliance , Polyethylene Glycols , Recombinant Proteins , Retrospective Studies , Ribavirin/administration & dosage , Ribavirin/therapeutic use , Risk Factors , Substance-Related Disorders/complications , Treatment Outcome
13.
Infez Med ; 12(2): 136-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15316301

ABSTRACT

In renal allograft recipients, infection disease complications remain an important cause of morbidity and mortality during the post-transplant period. This complication occurs more frequently from 1 to 6 months after transplant. The epidemiology of infection during the postoperative period is less well characterized, because recipients routinely reside at home. We describe a case of late onset Candida albicans and HSV-1 esophagitis, and Pneumocystis carinii pneumonia, that occurs 9 years after renal transplantation in a patient with severe CD4+ T-lymphocytopenia and hypogammaglobulinaemia. We underline the importance of monitoring immunosuppressive therapy in these patients and the usefulness of prophylaxis against P. carinii pneumonia


Subject(s)
Bacteremia/microbiology , Kidney Transplantation , Opportunistic Infections/etiology , Pneumonia, Pneumocystis/etiology , Postoperative Complications/microbiology , Pseudomonas Infections/etiology , Agammaglobulinemia/etiology , Aged , CD4 Lymphocyte Count , Fatal Outcome , Glomerulonephritis, Membranoproliferative/surgery , Heart Failure/etiology , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Lymphopenia/etiology , Male , Pseudomonas Infections/microbiology
14.
J Nephrol ; 17(2): 296-301, 2004.
Article in English | MEDLINE | ID: mdl-15293532

ABSTRACT

BACKGROUND: The role of leishmaniasis in dialyzed or transplanted patients for chronic renal failure is generally neglected. In this study, the authors present a series of three cases of leishmaniasis (one visceral, one mucous and one muco-visceral) in patients with end-stage renal failure characterized by an atypical presentation and/or resistance to therapy. CASE DESCRIPTION: Two patients had an atypical infection: the first patient demonstrated a mucosal form, while the second had visceral and mucosal involvement. These two presentations are very rare and, to the best of our knowledge, other autoctonous disease cases have never been described in Italy. In the first patient, a cycle of oral itraconazole was scarcely effective and poorly tolerated, while treatment with 15% topical paromomycin sulfate was successful. Patients two and three failed to respond to meglumine antimonate and amphotericin B lipid complex. A second cycle with liposomal amphotericin B was effective in both cases. In addition, a superior safety profile for liposomal amphotericin B in comparison with the lipid complex amphotericin B was observed. CONCLUSIONS: These three cases highlight the problem of leishmaniasis in both renal transplanted and dialyzed patients and suggest that this infection could be far from infrequent in addition to being resistant to therapies. Leishmaniasis should be considered in the differential diagnosis of fevers of unknown origin and mucosal lesions in these patients, even in countries not at risk for mucosal leishmaniasis.


Subject(s)
Kidney Failure, Chronic/complications , Leishmaniasis/diagnosis , Amphotericin B/therapeutic use , Antiprotozoal Agents/therapeutic use , Biopsy , Bone Marrow Examination , Humans , Kidney Failure, Chronic/therapy , Kidney Transplantation , Leishmaniasis/complications , Leishmaniasis/drug therapy , Male , Middle Aged , Renal Dialysis , Treatment Outcome
16.
Recenti Prog Med ; 95(4): 200-3, 2004 Apr.
Article in Italian | MEDLINE | ID: mdl-15147065

ABSTRACT

Most sore throat is due to viral upper respiratory tract infections, whereas the frequency of antibiotic use in adult patients is about 73%. We evaluate the clinical guidelines (approved by the CDC) about appropriate antibiotic use for acute pharyngitis in young adults. We observe a low prevalence (3,2%) of group A beta haemolytic streptococcus (GABHS) in a population of university students. Minimizing unnecessary antimicrobial therapy in this setting is highly desirable. Use of clinical criteria (Centor algorithm) does indeed identify patients whose risk for GABHS infection is so low that microbiological testing or antibiotic treatment is unnecessary.


Subject(s)
Algorithms , Pharyngitis/diagnosis , Pharyngitis/microbiology , Streptococcal Infections/diagnosis , Streptococcus pyogenes , Adult , Female , Humans , Male , Practice Guidelines as Topic
17.
Recenti Prog Med ; 95(1): 11-4, 2004 Jan.
Article in Italian | MEDLINE | ID: mdl-15032335

ABSTRACT

According to the National Nosocomial Infection Surveillance system we analysed the post-surgical nosocomial infections in a surgery ward of Perugia University. Between May 2000 and April 2001, 677 patients were enrolled mean age 51.5 years: 355 (52%) male, 462 (68%) ASA score 1, "clean" surgery in 355 cases (52%), cephazolin prophylaxis in 256 (38%); 11 (2%) patients deceased perioperatively. A total of 37 nosocomial infections, in 33 patients, were detected: 18 pneumonia (48.6%), 10 surgical site infections (27%) with 18 isolated: 12 gram-negative (E. coli 3, Acinetobacter baumannii 2, Providencia stuartii 2, Pseudomonas aeruginosa 2, Achromobacter spp. 1, Citrobacter freundii 1, Morganella morgani 1) and 6 gram-positive (Staphylococcus aureus meticillin resistant 3, Enterococcus faecalis 2, Streptococcus salivarius 1); 7 sepsis (19%) due to 7 gram-positive (S. aureus meticillin resistant 4, S. aureus meticillin susceptible 1, Staphylococcus coagulase negative 1, Clostridium spp 1), 2 urinary tract infections (5.4%). Patients without infections and with nosocomial infections spent in hospital 6.3 and 16.6 days respectively. We can image that in one year 53 surgical procedure were lost, with a lost gain of 79.500-291.500 euro/year.


Subject(s)
Bacterial Infections/epidemiology , Cross Infection/epidemiology , Female , Humans , Male , Middle Aged , Surgery Department, Hospital
18.
Infez Med ; 12(4): 270-3, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15729018

ABSTRACT

In this report we describe three cases of Aspergillus flavus sternal wound infection following cardiac surgery. All three cases occurred in a 3-month period coinciding with hospital renovation activities. The patients were successfully treated with combined surgical and medical therapy.


Subject(s)
Aspergillosis/etiology , Aspergillus flavus , Coronary Artery Bypass , Cross Infection/etiology , Heart Valve Prosthesis , Surgical Wound Infection/etiology , Aged , Humans , Male , Middle Aged
19.
J Neurovirol ; 10(6): 414-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15765813

ABSTRACT

Epstein-Barr Virus (EBV) encephalitis is a rare (<1%) and generally self-limited disease with few sequelae. This neurological complication has been reported almost exclusively in the course of acute primary infection and in paediatric patients. We describe a case of a young adult immunocompetent man who developed an acute fatal necrotizing haemorrhagic encephalitis as the only manifestation of an acute EBV infection. EBV-DNA was tested positive in several CSF samples by qualitative and quantitative PCR. Serological profile showed: absence of IgM against Viral Capsid Antigen (VCA) in three different consecutive samples, presence of IgG against VCA and IgG seroconversion for Epstein Barr Nuclear Antigen (EBNA). EBV-DNA was detected by qualitative PCR in autoptic brain material. Clinical course was not influenced by antiviral therapy with acyclovir. In conclusion to our knowledge, this is the only case of acute necrotizing haemorrhagic EBV encephalitis with a fatal outcome, in an adult immunocompetent man.


Subject(s)
Antibodies, Viral/blood , Brain/pathology , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human/immunology , Leukoencephalitis, Acute Hemorrhagic/etiology , Adult , Antibodies, Viral/immunology , Antigens, Viral/immunology , Brain/virology , DNA, Viral/analysis , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/pathology , Fatal Outcome , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Leukoencephalitis, Acute Hemorrhagic/pathology , Magnetic Resonance Imaging , Male , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...